The Mayo Clinic Cancer Center Pharmacy Shared Resource provides comprehensive pharmacy services in support of approximately 200 active cancer clinical trials across the 3 campuses of Mayo Rochester, Mayo Jacksonville, and Mayo Sccttsdale. The Pharmacy Shared Resource provides procurement, storage, and accountability of investigational agents. In addition, admixture of cytotoxic chemotherapy, growth factors, immunomodulatory agents, antiemetics, and supportive care medication is provided. The services of the Pharmacy Shared Resource are essential for protocol development, protocol initiation, and patient treatment on clinical trials throughout the Mayo Clinic Cancer Center. Special expertise with both investigational and commercially available cancer therapeutic agents resides in the Cancer Center Pharmacy Shared Resource, ensuring a uniformly high standard of safe and accurate treatment for all Mayo Clinic cancer patients. The utilization of the Pharmacy Shared Resource has increased over the past five years as noted by the number of patients treated on clinic trials. In 2002 the number of patients treated on clinical trials at the Mayo Clinic Cancer Center that utilized the Pharmacy Shared Resource was 1549, compared to 573 in 1997. This increase was due to the steady increase in patient accrual and the integration of Mayo Clinic Jacksonville and Mayo Clinic Scottsdale. The increased utilization of the Pharmacy Shared Resource is also demonstrated by an increased number of Mayo Clinic Cancer Center members utilizing the services of the Pharmacy core as well as the increased number of protocols in development. The main mission of the Pharmacy Shared Resource is to provide protocol development and review, investigational drug accountability, and chemotherapy admixture and dispensing services. The implementation of policies and procedures consistent with American Society of Health Systems Pharmacy guidelines and Joint Commission on Accreditation of Healthcare Organizations recommendations at each site ensures regulatory compliance and provides a uniform level of safe, high quality care to all Mayo Clinic Cancer Center patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-32
Application #
7253309
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
32
Fiscal Year
2006
Total Cost
$136,992
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications